|
Rosetta Genomics Ltd. is a molecular diagnostics company with offices in Israel and the United States that uses micro-ribonucleic acid (microRNA) biomarkers to develop diagnostic tests designed to differentiate between various types of cancer.〔Chambers, Heather. "Isis, Alnylam Pair To Seek Disease-Fighting Drugs." ''San Diego Business Journal'', September 17, 2007.〕 The company expects the first three tests based on its technology to be submitted for regulatory approval in 2008.〔"Columbia University Medical Center and Rosetta Genomics Announce Columbia University's Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinical Laboratory Evaluation Program," Forbes.com, April 3, 2008〕 The diagnostic tests will differentiate between squamous and non-squamous non-small cell lung cancer (NSCLC); differentiate between adenocarcinoma and peritoneal mesothelioma;〔"Rosetta Genomics Ltd. Completes Prevalidation Phase for First Diagnostic Production." ''Reuters'', October 30, 2007.〕 and seek to identify the origin of tumors in patients representing cancer of unknown primary (CUP).〔Boggs, Jennifer. "Rosetta Genomics' IPO Raising $26.3M For MicroRNA Work."''BioWorld Today'', February 28, 2007.〕 Using a single microRNA, the highly sensitive, highly specific test for squamous and non-squamous lung cancer has passed the prevalidation phase 〔 and has been submitted for approval to the New York State Department of Health Clinical Laboratory Evaluation Program in April 2008.〔 In April 2008, ''Nature Biotechnology'' published a study by Rosetta Genomics’ scientists whose findings demonstrate microRNAs' significant potential to act as effective biomarkers that may be applied in a diagnostic test designed to identify the primary tumor site in patients CUP.〔 〕 In addition to its diagnostic programs, Rosetta Genomics is collaborating with Isis Pharmaceuticals to develop a microRNA-based therapy for Hepatocellular carcinoma (HCC), a form of liver cancer.〔"Antisense Oligonucleotide, Heptacellular carcinoma, Isis/Rosetta Genomics Isis, Rosetta Genomics Licensing Agreement." ''R&D Focus Drug News'', March 6, 2006.〕 ==Intellectual property== Rosetta Genomics has developed a microRNA discovery process combining powerful informatics with high-throughput biological techniques.〔 〕 This has led to the discovery of a large portion of today’s known human and viral microRNAs.〔http://money.cnn.com/news/newsfeeds/articles/prnewswire/200804280830PR_NEWS_USPR_____UKM006.htm "Rosetta Genomics Announces Expansion Of Its MicroRNA Intellectual Property Estate," CNNMoney.com, April 28, 2008.〕 In 2007, the U.S. Patent and Trademark Office issued Rosetta Genomics with two patents relating to microRNAs. In March 2008, Rosetta Genomics announced that the U.S. Patent and Trademark Office has issued allowance for two of the company's patent applications on human and viral microRNAs.〔 http://news.moneycentral.msn.com/provider/providerarticle.aspx?feed=BCOM&date=20080303 &id=8270968&cid=1138847682&ei=PTnMR4z2N5GO8AK98LyMCQ "Market Report--In Play (WIRES)," msnmoney.com, March 2008.〕〔http://www.uspto.gov/web/patents/patog/week20/OG/html/1318-3/US07217807-20070515.html USPTO Web site, "USPTO Patent Full-text and Image Database"〕 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Rosetta Genomics」の詳細全文を読む スポンサード リンク
|